0.9137

2.65% +0.0236

VolitionRX Ltd (VNRX)

Overview News Price History Option Chain Discussions Forecast

VolitionRX Ltd stock is currently priced at $0.9137, with a 24-hour trading volume of 209.15K. It has seen a +2.65% increased in the last 24 hours and a +21.86% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.8967 pivot point. If it approaches the $1.01 resistance level, significant changes may occur.

Previous Close:

$0.8902

Open:

$0.909

24h Volume:

209.15K

Market Cap:

$74.99M

Revenue:

$775.30K

Net Income/Loss:

$-35.32M

P/E Ratio:

-1.6316

EPS:

-0.56

Net Cash Flow:

$-19.15M

1W Performance:

+48.33%

1M Performance:

+21.86%

6M Performance:

+24.31%

1Y Performance:

-42.89%

1D Range:

$0.8645

$0.9261

52W Range:

$0.55

$2.10

VolitionRX Ltd Stock (VNRX) Company Profile

Name

VolitionRX Ltd

Sector

Healthcare (1191)

Industry

Diagnostics & Research (66)

Phone

646 650 1351

Address

No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX

Employee

Twitter

@VolitionRx

Next Earnings Date

2024-05-08

Latest SEC Filings

VNRX's Discussions on Twitter

VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-01-23	Downgrade	The Benchmark Company	Buy → Hold
Feb-17-22	Resumed	Cantor Fitzgerald	Overweight
Mar-10-21	Initiated	Cantor Fitzgerald	Overweight
May-16-18	Initiated	Maxim Group	Buy
May-14-18	Reiterated	The Benchmark Company	Buy
Sep-07-16	Reiterated	Rodman & Renshaw	Buy
Feb-01-16	Initiated	Rodman & Renshaw	Buy

View All

VolitionRX Ltd Stock (VNRX) Latest News

Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket

Benzinga

IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying

Benzinga

Ondas Holdings And 2 Other Stocks Under $1 Insiders Are Buying

Benzinga

VolitionRX Ltd Stock (VNRX) Financials Data

VolitionRX Ltd (VNRX) Revenue 2024

VNRX reported a revenue (TTM) of $775.30 thousand for the quarter ending December 31, 2023, a +153.04% rise year-over-year.

VolitionRX Ltd (VNRX) Net Income 2024

VNRX net income (TTM) was -$35.32 million for the quarter ending December 31, 2023, a -16.68% decrease year-over-year.

VolitionRX Ltd (VNRX) Cash Flow 2024

VNRX recorded a free cash flow (TTM) of -$19.15 million for the quarter ending December 31, 2023, a -13.64% decrease year-over-year.

VolitionRX Ltd (VNRX) Earnings per Share 2024

VNRX earnings per share (TTM) was -$0.51 for the quarter ending December 31, 2023, a +7.27% growth year-over-year.

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.